BioVersys is actively seeking new partners for collaboration and licensing.
Since May 2014, BioVersys is collaborating with GlaxoSmithKline on preclinical candidates against tuberculosis. The collaboration uses BioVersys' TRIC technology for the discovery of compounds and is funded by the Wellcome Trust. The common project will advance molecules that reactivate the efficacy of established tuberculosis therapies. Financial details of the agreement are not disclosed. For further information, please click here.Official Website
Under the umbrella of the SATT Nord (Société d'accélération de transfert de technologie) in France, BioVersys collaborates with leading scientists in the Tuberculosis field at the Institut Pasteur de Lille, the University Lille and at INSERM (institut national de santé et de la recherche médicale).Official Website